Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting EZH2 in cancer
Kimberly H. Kim, Charles W.M. Roberts
Nature Medicine (2016) Vol. 22, Iss. 2, pp. 128-134
Open Access | Times Cited: 1272

Showing 1-25 of 1272 citing articles:

Epigenetic plasticity and the hallmarks of cancer
William Flavahan, Elizabeth Gaskell, B Bernstein
Science (2017) Vol. 357, Iss. 6348
Open Access | Times Cited: 1150
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip J. Gotwals, Scott B. Cameron, Daniela Cipolletta, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 286-301
Closed Access | Times Cited: 867
Small-cell lung cancer: what we know, what we need to know and the path forward
Adi F. Gazdar, Paul A. Bunn, John D. Minna
Nature reviews. Cancer (2017) Vol. 17, Iss. 12, pp. 725-737
Closed Access | Times Cited: 738
Ewing sarcoma
Thomas G. P. Grünewald, Florencia Cidre‐Aranaz, Didier Surdez, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 648
The great escape: tumour cell plasticity in resistance to targeted therapy
Soufiane Boumahdi, Frédéric J. de Sauvage
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 1, pp. 39-56
Closed Access | Times Cited: 602
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 545
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Priya Mittal, Charles W.M. Roberts
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 435-448
Open Access | Times Cited: 472
Epigenetic balance of gene expression by Polycomb and COMPASS families
Andrea Piunti, Ali Shilatifard
Science (2016) Vol. 352, Iss. 6290
Open Access | Times Cited: 467
Epigenetic modifications of histones in cancer
Zibo Zhao, Ali Shilatifard
Genome biology (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 448
Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 435
Epigenetic Therapies for Cancer
Susan E. Bates
New England Journal of Medicine (2020) Vol. 383, Iss. 7, pp. 650-663
Closed Access | Times Cited: 388
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair Davies, Himisha Beltran, Amina Zoubeidi
Nature Reviews Urology (2018) Vol. 15, Iss. 5, pp. 271-286
Closed Access | Times Cited: 356
The emerging role of epigenetic therapeutics in immuno-oncology
Michael J. Topper, Michelle Vaz, Kristen A. Marrone, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 2, pp. 75-90
Open Access | Times Cited: 344
Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential
Lu Gan, Yanan Yang, Qian Li, et al.
Biomarker Research (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 336
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli, Ewa Gogola, Hatice Yücel, et al.
Nature Cell Biology (2017) Vol. 19, Iss. 11, pp. 1371-1378
Closed Access | Times Cited: 301
The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer
Zhongwei Li, Pingfu Hou, Dongmei Fan, et al.
Cell Death and Differentiation (2016) Vol. 24, Iss. 1, pp. 59-71
Open Access | Times Cited: 297
The roles of Polycomb repressive complexes in mammalian development and cancer
Andrea Piunti, Ali Shilatifard
Nature Reviews Molecular Cell Biology (2021) Vol. 22, Iss. 5, pp. 326-345
Closed Access | Times Cited: 295
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
Daniel Zingg, Natalia Arenas-Ramirez, Dilara Şahin, et al.
Cell Reports (2017) Vol. 20, Iss. 4, pp. 854-867
Open Access | Times Cited: 285
Dynamics of BAF–Polycomb complex opposition on heterochromatin in normal and oncogenic states
Cigall Kadoch, Christina Williamson, Joseph P. Calarco, et al.
Nature Genetics (2016) Vol. 49, Iss. 2, pp. 213-222
Open Access | Times Cited: 271
Marked for death: targeting epigenetic changes in cancer
Sophia X. Pfister, Alan Ashworth
Nature Reviews Drug Discovery (2017) Vol. 16, Iss. 4, pp. 241-263
Closed Access | Times Cited: 268
The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p
Mu Xu, Xiaoxiang Chen, Lin Kang, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 263
Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
David Wang, Jason Quiros, Kelly Mahuron, et al.
Cell Reports (2018) Vol. 23, Iss. 11, pp. 3262-3274
Open Access | Times Cited: 258
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Aaron R. Lim, W. Kimryn Rathmell, Jeffrey C. Rathmell
eLife (2020) Vol. 9
Open Access | Times Cited: 239
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Glenn J. Hanna, Patrick H. Lizotte, Megan E. Cavanaugh, et al.
JCI Insight (2018) Vol. 3, Iss. 4
Open Access | Times Cited: 236
PRC2 is high maintenance
Jia-Ray Yu, Chul‐Hwan Lee, Ozgur Oksuz, et al.
Genes & Development (2019) Vol. 33, Iss. 15-16, pp. 903-935
Open Access | Times Cited: 235
Page 1 - Next Page

Scroll to top